ClinicalTrials.gg

Program

ceralasertib

Also written as “Ceralasertib”, “Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).” and “[14C] AZD6738”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Triple Negative Breast Neoplasms · Neoplasms · Leukemia, Lymphocytic, Chronic, B-Cell · Melanoma, led by AstraZeneca.

Furthest: phase 3, since Jul 6, 202216 company-led studies, 7 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca167 open or runningphase 3since Jul 6, 2022Sep 30, 2013none ahead

Also a collaborator on its studies: parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Sep 30, 2013.

  1. Jan 13, 2017Phase 1 study in Squamous Cell Carcinoma of Head and NeckNCT03022409 · 21 enrolled · United States, France, Taiwan
  2. Sep 22, 2017Phase 2 study in Carcinoma, Non-Small-Cell LungNCT03334617 · 528 enrolled · United States, Austria, Canada and more
  3. Oct 16, 2017Phase 2 study in Triple Negative Breast NeoplasmsNCT03330847 · 273 enrolled · United States, Belgium, Canada and more
  4. Oct 30, 2017Phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellNCT03328273 · 12 enrolled · Poland, United Kingdom
  5. Apr 24, 2018Phase 1 study in Lymphoma, Non-HodgkinNCT03527147 · 30 enrolled · United States, United Kingdom
  6. Jan 21, 2020Phase 2 study in Ovarian NeoplasmsNCT04239014 · United States, Canada, Italy and more
  7. Sep 8, 2020Phase 2 study in Hereditary Sensory and Autonomic NeuropathiesNCT04564027 · 54 enrolled · United States, France, Spain
  8. Sep 22, 2021Phase 2 study in MelanomaNCT05061134 · 194 enrolled · United States, Australia, Belgium and more
  9. May 18, 2022Phase 1 study in Advanced Solid MalignanciesNCT05469919 · 12 enrolled · Japan
  10. Jul 6, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05450692 · 594 enrolled · United States, Argentina, Australia and more
  11. Aug 23, 2022Phase 1 study in Advanced Solid TumoursNCT05514132 · 14 enrolled · China
  12. Jun 12, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05941897 · 39 enrolled · Russia
  13. Nov 4, 2024Phase 1 study in NeoplasmsNCT06754761 · 2 enrolled · United Kingdom
  14. Apr 14, 2025Phase 1 study in Advanced Solid TumoursNCT06929260 · 1 enrolled · United Kingdom

TargetBeta

ATR →read by rule
“An orally available morpholino-pyrimidine-based inhibitor of ataxia telangiectasia and rad3 related (ATR) kinase, ”NCIt, by rule
“Serine-protein kinase ATR inhibitor”ChEMBL 37, by rule

Other programs on ATR

ProgramCompanyFurthest phaseStudies
TCC1727Sino Biopharmaceuticalphase 22
FXS887ruleFosun Pharmaphase 11

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06929260Advanced Solid Tumours · United Kingdom1TerminatedOct 15, 20251
NCT06754761Neoplasms · United Kingdom1TerminatedOct 21, 20252
NCT05941897Carcinoma, Non-Small-Cell Lung · Russia2Active, not recruitingJul 29, 202439
NCT05514132Advanced Solid Tumours · China1Active, not recruitingOct 20, 202314
NCT05450692Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingOct 6, 2025594
NCT05469919Advanced Solid Malignancies · Japan1CompletedAug 17, 202312
NCT05061134Melanoma · United States, Australia, Belgium and more2Active, not recruitingApr 12, 2024194
NCT04564027Hereditary Sensory and Autonomic Neuropathies · United States, France, Spain2CompletedFeb 18, 202554
NCT04239014Ovarian Neoplasms · United States, Canada, Italy and more2WithdrawnJan 25, 20210
NCT03527147Lymphoma, Non-Hodgkin · United States, United Kingdom1CompletedMar 31, 202130
NCT03328273Leukemia, Lymphocytic, Chronic, B-Cell · Poland, United Kingdom1Active, not recruitingSep 7, 202112
NCT03330847Triple Negative Breast Neoplasms · United States, Belgium, Canada and more2Active, not recruitingNov 13, 2020273
NCT03334617Carcinoma, Non-Small-Cell Lung · United States, Austria, Canada and more2Active, not recruitingSep 13, 2024528
NCT03022409Squamous Cell Carcinoma of Head and Neck · United States, France, Taiwan1CompletedJan 20, 202121
NCT02937818Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma · Germany, Hungary, Poland and more2CompletedJun 22, 202072
NCT01955668Leukemia, B-Cell · United States1CompletedDec 20132

How it is read

Names in the registry

  • “Ceralasertib”, 11 entries
  • “Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).”, 1 entry
  • “[14C] AZD6738”, 1 entry
  • “AZD6738 / ceralasertib”, 1 entry
  • “AZD6738 and olaparib”, 1 entry

Codes read as this program: AZD6738.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.